Gordon, John R - University of Saskatchewan

个人简介

Dr. John Gordon received his PhD in immunopathology from the University of Saskatchewan in 1984. He did post-doctoral fellowships at the National Institute for Medical Research at Mill Hill, UK (1984-87) and the Department of Pathology at Harvard Medical School (1987-88), then worked as an Instructor in the Department of Pathology at the latter institution (1988-91). He returned to the University of Saskatchewan in 1991 as an Associate Professor in the Department of Veterinary Microbiology. In 2007 he moved to the Department of Medicine as the Director of the Canadian Centre for Health and Safety in Agriculture (2007-12), after which he served as Acting Associate Dean Research for the College of Medicine (2012-13). He is presently a Professor in the Division of Respirology, Critical Care and Sleep Medicine, Department of Medicine. Dr. Gordon’s laboratory focus is immunotherapeutics in the context of allergic and other inflammatory diseases. They have developed regulatory dendritic cell protocols to reverse asthma and food allergen sensitivity in animal models and have shown that these approaches are relevant also to human disease. They are presently moving to translate regulatory dendritic cell immunotherapies into the clinic. Their lab also patented a series of anti-inflammatory drugs that attenuate neutrophilic inflammation in an array of animal models, but they have more recently shown that these same agents potently antagonize the growth, metastasis and development of chemotherapeutic resistance in multiple tumours. Dr. Gordon’s lab has been funded for >25 years by the Canadian Institutes for Health Research (CIHR), but is also funded by the Natural Sciences and Engineering Research Council (NSERC) of Canada, the Canadian Foundation for Innovation, the Canadian Cystic Fibrosis Foundation (CCFF), the Saskatchewan Health Research Foundation (SHRF) and AllerGen NCE. Dr. Gordon devotes considerable time and energy to mentoring trainees within his own laboratory. He was also a co-Leader of the SHRF Airways Research Group and the Scientific Director of a multinational CIHR Strategic Training Program in Health Research. He is the Vice-president of the Canadian Society for Immunology, and has served on the Boards, management or review committees of the Gairdner Foundation, AllerGen NCE and the CIHR Immunol & Transplantation grant panel among others.

研究领域

Respiratory Immunology and Inflammation (pathogenesis) Allergy Asthma Immunotherapeutics Dendritic cells Regulatory T cells Th2 cells Neutrophils

近期论文

查看导师最新文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Z.E. Gillespie, K. MacKay, M. Sander, B. Trost, W. Dawicki, A. Wickramarathna, J.R. Gordon, I. Kill, J. Bridger, A. Kusalik, J.A. Mitchell, C.H Eskiw. 2016. Rapamycin reduces fibroblast proliferation without causing quiescence and induces STAT5A/B-mediated cytokine production. Nucleus 6:490-506 B.J. Connell1, J.R. Gordon, T.M. Saleh. 2015. ELR-CXC chemokine antagonism is neuroprotective in a rat model of ischemic stroke. Neurosci Lett 606:117-22 M. Asaduzzaman, A. Nadeem, N. Arizmendi, C. Davidson, H. Nichols, M. Abel, L. Ionescu, L. Puttagunda, B. Thebaud, J.R. Gordon, K. Defea, M. Hollenberg, & H. Vliagoftis. 2015. Functional inhibition of PAR2 alleviates allergen-induced airway hyperresponsiveness and inflammation. Clin Exp Allergy 45:1844-55 M. Khan, B. Wang, J. Wei, Y Zhang, Q. Li, X. Luan, J-W. Cheng, J.R. Gordon, F. Li, and H. Liu. 2015. CXCR1/2 antagonism with a CXCL8 analogue CXCL8(3-72)K11R/G31P restricts lung cancer growth by inhibiting tumour cell proliferation and suppressing angiogenesis. Oncotarget 6:21315-27 L. Li, M.N. Khan, Q. Li, X. Chen, J. Wei, B. Wang, J.W. Cheng, J.R. Gordon, F. Li. 2015. G31P, CXCR1/2 inhibitor, with cisplatin inhibits the growth of mice hepatocellular carcinoma and mitigates high‑dose cisplatin-induced nephrotoxicity. Oncol Rep 33:751-7 D. Schneberger, J.R. Gordon, A.J. Heires, J.D.DeVasure, J.A. Boten, D.J. Romberger, T.A. Wyatt. 2015. CXCR1/CXCR2 antagonist CXCL8(3-74)K11R/G31P blocks lung inflammation in swine barn dust-instilled mice. Pulm Pharmacol Therap 31:55-62 S.A. Ballendine, Q. Greba, W. Dawicki, X. Zhang, J.R. Gordon, J.G. Howland. 2015. Behavioral alterations in rat offspring following maternal immune activation and ELR-CXC chemokine receptor antagonism during pregnancy: implications for neurodevelopmental psychiatric disorders. Prog Neuro-psychopharm Biol Psych 57:155-65 P. Novakovic, Y.Y. Huang, B. Lockerbie, F. Shahriar, J. Kelly, J.R. Gordon, D.M. Middleton, M.E. Loewen, B.A. Kidney, and E. Simko. 2015. Identification of F4ac-binding proteins of porcine milk fat globule membranes. Canadian Journal of Veterinary Research 79:120-8 J.R. Gordon, Y. Ma, L. Churchman, S.A. Gordon and W. Dawicki. 2014. Regulatory dendritic cells for immunotherapy in immunologic diseases. Frontiers in Immunology 5: 7 (12 pp; doi: 10.3389/fimmu.2014.00007) (Invited Review) J. Wei, X Chen, Q Li, J Chen, N Khan, B. Wang, J-W Cheng, JR Gordon and F Li. ELR-CXC chemokine antagonism and cisplatin co-treatment additively reduce H22 hepatoma tumor progression and ameliorate cisplatin-induced nephrotoxicity. 2014. Oncol. Reports 31:1599-604